Intestinal extracts of pigs make Haipurui biopharmaceutical the new favorite of PEVC

Business News Agency July 25th Heparin sodium is an anticoagulant drug. The world's largest raw heparin sodium supplier is Haipu Rui who has high-profile access to A shares. Li Li has thus become a worthy of 23.711 billion biomedical drugs. The richest man in the industry.

Interestingly, the creation of the richest man turned out to be the intestinal mucosa of pigs or cattle from which heparin sodium can be extracted.

The heparin sodium extracted from the healthy bovine small intestine is consistent with the molecular structure of human heparin and can be used for kidney dialysis and various surgical operations. This is the most important source of profit for Haipurui, and Haipurui is the only FDA approved to enter the US market. Heparin API company.

As early as the third grade in university, Li Li began to study the purification of heparin sodium. This technology is his most unquestionable pride. He and his wife Li Tan met in the Department of Chemistry at Sichuan University. Li Tan’s brother, Yu Yu, graduated from Peking University with a specialization in radiochemistry. He is currently the general manager of Hai Purui. When Li Yu met with Li Li for the first time, he was surprised by his research knowledge and vision. , "He told me to dizzy."

It is said that when Li Li left Chongqing Tongda, his wealth had exceeded 20 million. Hai Purui introduced PE to start with Yang Xiangyang.

Yang Xiangyang and Shan Yu were small playmates, and their parents had studied in Yiyang, Anhui Province. Yang Xiangyang focused on the investment in the biomedical industry and was also concerned about investing in 40% of Lenovo Mobile. Hai Purui's early capital operation was basically led by Yang Xiangyang. As to why he withdrew before the IPO, he did not want to go into details.

Biomedicine is an industry with professional barriers. It is as large as genetic engineering and as small as a cold medicine. The requirements for PE and VC have also increased. It seems that Yang Xiangyang is one of the few who dare to take risks. This is one of the reasons why Haipurui chose to cooperate with Goldman Sachs. Goldman Sachs has investment banks and analysts who are familiar with the pharmaceutical industry and really understand the heparin sodium industry chain.

Some people say that biopharmaceuticals are essential consumer goods, and investment funds are certainly tilting here. However, most biopharmaceutical products in China are concentrated on imitation vaccines and blood products. The downstream and foreign countries have more than ten years of distance, and no industrial clusters have yet formed. There are also many PEs/VCs that have invested in this area earlier, but only a handful of special funds can be established until they can wait for drug development until they are approved for production.

In the future, biopharmaceuticals may undergo industrial integration and mergers and acquisitions. The 12th Five-year Plan for Biomedicine is currently under review and is expected to be introduced at the end of the month. According to the plan, as one of the seven strategic emerging industries, bio-pharmaceuticals will have an industrial output value of more than 3.6 trillion yuan by 2015.

PE/VCs were also among the few who heard the news. At the end of last year, Tianjin Venture Capital and Yinke Venture Capital respectively cooperated with foreign companies and established venture capital funds, focusing on biomedicine. Tianjin Venture Capital and Israel’s Infiniti Corporation jointly manage Tianjin Tianyi Bio-Medical Equity Investment Fund with a registered capital of RMB 10.1 million. The Chengdu Government Investment Fund Yinke Venture Capital Co., Ltd. and the United States peacekeeping venture capital management company, set up a sub-fund - Wei Ye (Chengdu) Biotechnology Venture Capital Co., Ltd., a total of 100 million yuan.

It is understood that many of PE/VC's key investment areas include biomedicine. Who will distribute the 3.6 trillion cakes in the future? We will wait and see.